Indefinite Delivery Contract SPE2DB24D9638

The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) valued at up to $499,999,999 to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract, which runs through December 31, 2025, enables DLA to issue firm fixed-price delivery orders for a broad range of pharmaceutical products to support the recurring medical supply needs of military health facilities worldwide.

Key product categories include branded and generic medications across nearly every therapeutic class, such as naltrexone tablets, botulinum toxin injections, contraceptive implants and intrauterine devices, chemotherapy drugs, HIV antiretrovirals, ophthalmic solutions, injectable anesthetics, and more. The contract also covers specialized biologics requiring cold chain logistics, as well as other medical supplies like surgical detergents and artificial tears. This IDC complements DMS Pharmaceutical Group's existing prime vendor contracts for direct distribution of prescription drugs and pharmacy services to Department of Defense sites.